China Dental Fluoride Treatment Market Analysis

China Dental Fluoride Treatment Market Executive Summary

The China Dental Fluoride Treatment Market is at around $1219.2 Mn in 2023 and is projected to reach $1761.9 Mn in 2030, exhibiting a CAGR of 5.4% during the forecast period 2023-2030.

Dental hygienists and dentists professionally apply high-concentration fluoride products to teeth in order to build enamel and prevent tooth decay. This procedure is known as a dental fluoride treatment. During routine dental appointments, they are usually applied as a gel, foam, varnish, or solution. Fluoride fortifies enamel and increases teeth's resistance to bacterial acid attacks by enhancing the absorption of minerals like calcium and phosphate. It also inhibits the growth of cavity-causing bacteria, slowing or stopping their destructive effects. Fluoride is a valuable tool in the fight against tooth decay and enamel deterioration.

Irritation, allergic reactions, and transient discolouration are possible adverse effects. Fluorosis can result from excessive consumption, especially in young infants. However, because over-the-counter drugs have modest concentrations, it is difficult to reach harmful amounts. Supplement acute poisoning can result in vomiting, diarrhoea, and in extreme circumstances, even death.

The prevalence of caries among children aged 5 years and 12 years was 70.1% and 34.5%, respectively, and the prevalence of periodontal disease among middle-aged and elderly people was 12.6%. market therefore is driven by significant factors like growing prevalence of dental caries coupled with increasing awareness regarding oral health and hygiene, increasing the intake of sugary drinks and food, cosmetic dentistry boom, technological advancements etc.

Some of the major players operating in the China Dental Fluoride treatment are Amway (China) Co. Ltd, Colgate-Palmolive Co, GlaxoSmithKline plc, Guangxi Aoqili Co. Ltd among others.

Market Dynamics

Market Drivers

Increasing prevalence of dental disorders: China has seen a rise in the incidence of dental caries, gum disease, and other oral health issues in recent years. The prevalence of caries among children aged 5 years and 12 years was 70.1% and 34.5%, respectively, and the prevalence of periodontal disease among middle-aged and elderly people was 12.6%. This increasing prevalence of dental disorders is likely driving the demand for effective preventive treatments like fluoride applications to address the growing oral health concerns.

Government initiatives and policies: The Chinese government has been actively promoting oral health awareness and improving access to dental care services through various initiatives and programs. These policies and programs aimed at increasing fluoride exposure, such as water fluoridation, could be supporting the growth of the dental fluoride treatment market by making it more accessible to the population.

Expanding middle-class and rising disposable incomes: The growing middle-class population in China and their increasing disposable incomes may be driving the demand for quality dental care, including fluoride treatments, as people seek to maintain good oral health. The ability to afford private dental services, including fluoride treatments, could be a key factor in the market's expansion.

Market Restraints

Access to dental care disparities: China has a large and diverse population, and access to quality dental services, including fluoride treatments, may not be uniform across all regions of the country. Disparities in access to care could limit the market potential in certain underserved or remote areas, hindering the overall growth of the dental fluoride treatment market.

Regulatory and reimbursement challenges:The regulatory environment and insurance coverage policies for dental care services in China may pose some challenges for the adoption and accessibility of fluoride treatments. Unfavourable or unclear regulations, as well as limited reimbursement coverage, could restrict the market's expansion.

Consumer awareness and acceptance: There may be a need to further increase consumer awareness about the benefits of fluoride treatments and address any safety concerns or misconceptions that the Chinese population may have. Overcoming any cultural or social barriers to the acceptance of fluoride treatments could be crucial for the market's growth.

Regulatory Landscape and Reimbursement Scenario

In China, the National Medical Products Administration (NMPA) is the primary regulatory authority responsible for the approval and oversight of medical devices, including dental products. The NMPA has implemented new regulations for toothpaste products, requiring them to undergo notification, testing, safety assessment, and efficacy evaluation before being allowed to be sold in the market. These regulations aim to enhance supervision and management of the toothpaste industry, combat false advertising, and align toothpaste regulations with those for general cosmetics.

In terms of reimbursement, China has a multi-tiered healthcare system that includes public insurance programs, private insurance, and out-of-pocket payments. The main public insurance programs are the Urban Employee Basic Medical Insurance (UEBMI), Urban Resident Basic Medical Insurance (URBMI), and New Rural Cooperative Medical Scheme (NRCMS), which provide coverage for a range of medical services, including some basic dental care, but the reimbursement levels vary.

Competitive Landscape

Key Players

Here are some of the major key players in the China Dental Fluoride Treatment Market:

• Amway (China) Co. Ltd.
• Colgate-Palmolive Co.
• GlaxoSmithKline plc
• Guangxi Aoqili Co. Ltd.
• Hawley & Hazel (BVI) Co. Ltd.
• Johnson & Johnson Ltd.
• Masson Group Co. Ltd.
• Procter & Gamble Co.
• Sunstar Suisse S.A.
• Unilever Group.